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Abstract
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides are rare systemic diseases that usually occur in
adulthood. They comprise granulomatosis with polyangiitis (GPA, Wegener’s), microscopic polyangiitis (MPA) and
eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss syndrome). Their clinical presentation is often
heterogeneous, with frequent involvement of the respiratory tract, the kidney, the skin and the joints. ANCA-
associated vasculitis is rare in childhood but North-American and European cohort studies performed during the
last decade have clarified their phenotype, patterns of renal involvement and their prognostic implications, and
outcome. Herein, we review the main clinical and therapeutic aspects of childhood-onset ANCA-associated
vasculitis, and provide preliminary data on demographic characteristics and organ manifestations of an Italian
multicentre cohort.
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Background
Primary systemic vasculitides comprise a group of disor-
ders characterised by the presence of inflammation af-
fecting the blood vessel wall, with resulting tissue
ischemia and necrosis. Systemic vasculitides are usually
classified based on the size of the predominantly in-
volved vessels into large-, medium- and small-vessel vas-
culitides. The most common large-vessel vasculitides are
Takayasu arteritis and giant cell arteritis; examples of
medium-sized vessel vasculitis are polyarteritis nodosa
and Kawasaki disease; finally, small-vessel vasculitides
include immune-complex mediated or hypersensitivity
forms (e.g. cryoglobulinemic vasculitis, IgA vasculitis/
Henoch-Schönlein purpura) and anti-neutrophil cyto-
plasmic antibody (ANCA)-associated vasculitis. All of
these forms, except for Kawasaki disease and IgA vascu-
litis, occur more frequently in the adult age and are ex-
tremely rare in childhood. Nevertheless, their
recognition, correct diagnosis and appropriate treatment
is crucial as they may be life- or organ-threatening [1].
ANCA-associated vasculitides (AAVs) are multisyste-
mic diseases and include microscopic polyangitiis
(MPA), granulomatosis with polyangiitis (GPA, formerly
Wegener’s granulomatosis) and eosinophilic granuloma-
tosis with polyangiitis (EGPA, formerly Churg-Strauss
syndrome). According to the revised Chapel Hill Con-
sensus Conference Nomenclature of vasculitides, AAV is
defined as a necrotising vasculitis with few or no im-
mune deposits, predominantly affecting small blood ves-
sels (i.e. capillaries, venules, and arterioles), associated
with the presence of circulating autoantibodies (ANCA)
that are usually directed against myeloperoxidase (MPO)
or proteinase 3 (PR3). PR3-ANCA account for the ma-
jority of ANCA with cytoplasmic immunofluorescence
patterns (C-ANCA) and are commonly associated with
GPA (60-80% of the cases), whereas MPO-ANCA usu-
ally match ANCA with perinuclear immunofluorescence
pattern (P-ANCA) and are more common in patients
with MPA (80-90% of the cases) or EGPA (35-40% of
the cases) [2]. Data on AAV in paediatric populations
are scarce, although recent cohort studies- mainly
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focusing on GPA and MPA and including up to 230
cases [3]- have greatly contributed to define the clinical
phenotype of paediatric AAV. Conversely, studies on
paediatric EGPA are limited to case reports or small
retrospective case series. Finally, clinical trials and long-
term outcome studies on all paediatric AAV forms are
lacking, except for retrospective analyses focusing mainly
on renal involvement. Herein, we provide an overview of
AAV in children, particularly focusing on clinical fea-
tures, kidney involvement, treatment and outcome.
Definitions and classification criteria
In 1990 the American College of Rheumatology (ACR)
proposed classification criteria for several (adult-onset)
systemic vasculitides, including GPA and EGPA [4, 5].
The vasculitis working group of the Paediatric Rheuma-
tology European Society (PReS) proposed the first classi-
fication criteria of vasculitis in children, endorsed by the
European League against Rheumatism (EULAR) in 2006
[6]. The general classification for childhood vasculitides
was based- as it is in adult patients- on the vessel size.
The small-vessel vasculitides were then subcategorised
into granulomatous and non-granulomatous (Table 1).
These proposed modifications were mainly based on a
literature review and not formally validated.
In 2008, at the Ankara Consensus Conference, a joint
effort of the EULAR, PReS and Paediatric Rheumatology
International Trials Organisation (PRINTO) societies
validated the EULAR-endorsed criteria and defined the
classification criteria for the four main paediatric vascu-
litides (IgA vasculitis, GPA, polyarteritis nodosa and
Takayasu arteritis). These classification criteria were
based on a collection of data of 1398 children from dif-
ferent centres. GPA was the only form of AAV whose
criteria were defined by the EULAR/PReS/PRINTO joint
committee. Three of the following six criteria were re-
quired to classify paediatric vasculitis as GPA: histopath-
ology (granulomatous inflammation within the arterial
wall or in the perivascular or extravascular area), upper
airway involvement (chronic purulent or bloody nasal
discharge or recurrent epistaxis/crusts/granulomata,
nasal septum perforation or saddle nose deformity,
chronic or recurrent sinus inflammation), laryngo-
tracheo-bronchial stenoses (subglottic, tracheal or bron-
chial stenosis), pulmonary involvement (chest x-ray or
CT showing the presence of nodules, cavities or fixed in-
filtrates), ANCA positivity by immunofluorescence or
ELISA (P-ANCA/MPO-ANCA or C-ANCA/PR3-
ANCA) and renal involvement (proteinuria > 0.3 g/24 h
or >30 mmol/mg of urine albumin/creatinine ratio on a
spot morning sample, haematuria or red blood cell casts
in the urinary sediment or ≥2+ on dipstick, or necrotis-
ing pauci-immune glomerulonephritis) (Table 2) [7, 8].
As compared with the ACR criteria for adult GPA, the
EULAR/PReS/PRINTO criteria mainly differed for the
addition of CT for a better characterisation of lung le-
sions and for the inclusion of more specific features for
respiratory tract complications.
No specific criteria for childhood-onset MPA and EGPA
have been formulated. In adults, different sets of criteria
have been proposed for EGPA, including the Lanham’s
criteria (asthma, eosinophil count >1.5x109/L and vascu-
litis involving two or more organs) [9] and the 1990 ACR
criteria (asthma, paranasal sinus abnormalities, eosino-
philia, lung infiltrates, peripheral neuropathy and extra-
vascular eosinophils on biopsy- with at least four of these
criteria required for the classification of vasculitis as
EGPA) [5]. Conversely, MPA has no defined classification
criteria in adults either. In 2007, Watts et al. developed a
four-step algorithm to permit classification of MPA, GPA,
EGPA and polyarteritis nodosa. This algorithm was
adopted by the European Medicines Agency (EMA) as a
practical tool for clinical trials and clinical study of adult
AAV and also for GPA and MPA in peadiatric patients
[10, 11]. No formal validation of the EMA algorithm for
EGPA is available for children; therefore, the diagnosis of
EGPA in childhood still relies on the empirical translation
of the adult classification systems.
Epidemiology
AAV has been mainly reported in adults. During the last
25 years, studies on the epidemiology of AAV in the
adult age have been reported from Europe, Japan, USA,
Table 1 Classification of childhood-onset vasculitis based on
the EULAR/PReS endorsed consensus criteria [6]
I Predominantly large-vessel vasculitis
• Takayasu arteritis
II Predominantly medium-sized vessel vasculitis
• Childhood polyarteritis nodosa
• Cutaneous polyarteritis
• Kawasaki disease
III Predominantly small-vessel vasculitis
(A) GRANULOMATOUS
• Wegener’s granulomatosis
• Churg-Strauss syndrome
(B) NON-GRANULOMATOUS
• Microscopic polyangiitis
• Henoch-Schönlein purpura
• Isolated cutaneous leucocytoclastic vasculitis
• Hypocomplementic urticarial vasculitis
IV Other vasculitides
• Behçet disease
• Vasculitis secondary to infection (including hepatitis B associated
polyarteritis nodosa), malignancies, and drugs, including hypersensivity
vasculitis
• Vasculitis associated with connective tissue diseases
• Isolated vasculitis of the central nervous system
• Cogan syndrome
• Unclassified
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New Zealand and Australia. The overall annual inci-
dence rates of AAV in Europe are reported to be in the
range of 13–20 cases/million [12]. In contrast, data in
children are scarce because most of the paediatric re-
ports are based on single-centre and national retrospect-
ive cohort studies and also because vasculitis in children
is extremely rare. The annual incidence of AAV reported
in a recent retrospective multicentre French study in-
cluding 66 children, the largest cohort in Europe, is ~0.5
per million children [13]. Higher incidence rates of up to
6.39 cases/million children/year were reported in a Can-
adian study [14]. Unlike in adults, where AAVs occur
more frequently in male than in female patients, child-
hood AAVs are more common in female subjects and
their onset peaks in the early second decade, with a me-
dian age at diagnosis of approximately 11–14 years [13].
These epidemiological characteristics were confirmed in
the largest series of paediatric AAV reported so far,
based on a North American multicentre study including
231 patients with MPA and GPA described by Cabral
and colleagues. In this study, children with MPA were
younger at diagnosis than those with GPA (median, 12
vs 14 years) [3]. Data on the epidemiology of EGPA are
limited; in a literature review of 33 cases reported by
Zwerina et al., childhood-onset EGPA was also more fre-
quent in females, with an M:F ratio of 0.7, and the mean
age at diagnosis was 12 years [15]. In terms of frequency,
GPA is the most frequent, followed by MPA and EGPA.
An examination of large databases (ARChiVe study)
reveals that childhood-onset EGPA accounts for less
than 2% of all cases of paediatric vasculitis [3].
Pathogenesis
The pathogenesis of AAV is not entirely clear. Genetic
susceptibility factors, environmental agents, as well as
abnormalities in innate and adaptive immune responses
appear to contribute to the development of AAV. A re-
cent genome-wide association study (GWAS) of 2687
Northern European Caucasian patients with GPA and
MPA suggested that GPA is associated with genetic vari-
ants within HLA-DP, SERPINA1 (encoding α1-
antitrypsin), and PRTN3 (encoding PR3), whereas MPA
is mainly associated with HLA-DQ [16]. Interestingly,
these associations were stronger with ANCA specificity
(PR3-ANCA and MPO-ANCA) than with the clinical
diagnosis of GPA or MPA, suggesting that the differ-
ences in the genetic background of the two AAV forms
were more closely related to the different ANCA profile
than to the clinical diagnosis. This observation, together
with the strong association of GPA with PRTN3 (which
encodes the autoantigen of PR3-ANCA) and with SER-
PINA1 (encoding α1-antitrypsin, the major system able
to catabolise PR3), suggested a central role of the auto-
antigen in the generation of ANCA and in the pathogen-
esis of AAV. [17] Several environmental agents are
known to predispose to or trigger AAV; among these are
air pollutants (especially silica), infections (Staphylococ-
cus aureus and viral infections) [18, 19] and drugs (e.g.
penicillamine, propylthiouracil, dapsone, cocaine adul-
terated with lemivasole) [20–23].
The pathogenesis is also based on defects in innate
and adaptive immunity with a dysregulation of B cells,
pathogenic production of ANCA, neutrophil activation
and an imbalance between helper T cell and effector T
cell responses. Neutrophils primed by infectious agents
and also activated by ANCA are the main cells initiating
Table 2 Final EULAR/PRINTO/PReS criteria for granulomatosis
with polyangiitis (GPA, Wegener’s) [8]
Criterion Glossary Sensitivity
(%)
Specificity
(%)
1-
Histopathology
Granulomatous inflammation
within the wall of an artery or
in perivascular or extravascular
area
54 99.6
2-Upper airway
involvement
Chronic purulent or bloody
nasal discharge or recurrent
epistaxis/crusts/granulomata
Nasal septum perforation o
saddle nose deformity
Chronic or recurrent sinus
inflammation
83 99
3-Laryngo-
tracheo-
bronchial
involvement
Subglottic, tracheal or
bronchial stenoses
22 99.8
4-Pulmonary
involvement
Chest x-ray or CT showing the
presence of nodules, cavities
or fixed infiltrates
78 92
5-ANCA ANCA positivity by
immunofluorescence or by
ELISA (MPO/p or PR3/c ANCA)
93 90
6-Renal
involvement
Proteinuria >0.3 g/24 ore or >
30 mmol/mg of urine
albumin/creatinine ratio on a
spot morning sample
Haematuria or red blood cell
casts: >5 red blood cells/high
power field or red blood cell
casts in the urinary sediment
or ≥2+ on dipstick
Necrotising pauci-immune
glomerulonephritis
65 69.6
Childhood-WG
EULAR/PRINTO/
PRES
Ankara 2008
classification
At least three of the six
following criteria:
Histopathology
Upper airway involvement
Laryngo-tracheo-bronchial
stenosis
Pulmonary involvement
ANCA positivity
Renal involvement
93.3 99.2
ANCA, anti-neutrophil cytoplasmic antibody; WG, Wegener granulomatosis;
EULAR, European League Against Rheumatism; PReS, Paediatric Rheumatology
European Society; PRINTO, Paediatric Rheumatology International
Trials Organisation
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endothelial cell and tissue damage, leading to inflamma-
tion of the vessel wall and- in GPA- granuloma forma-
tion [24]. Strong in vivo and in vitro evidence supports
the pathogenic role of ANCA. ANCAs are predomin-
antly immunoglobulin G (IgG) autoantibodies directed
against constituents of neutrophil primary granules and
lysosomes of monocytes. Animal models also exist that
recapitulate the main phenotypic features of MPA using
MPO-ANCA; on the other hand, the pathogenicity of
PR3-ANCA has not clearly been demonstrated in animal
models of vasculitis [24, 25]. Finally, a role of the
complement alternative pathway has recently been
demonstrated [24]. AAVs are traditionally considered
pauci-immune diseases, i.e. diseases characterised by
little or no immune deposits in the affected tissues.
However, recent studies have shown that C3 depos-
ition is not uncommon in patients with renal AAV,
and that it is the expression of complement alterna-
tive pathway activation with consequent generation of
chemotaxins (e.g. C3a, C5a) which are able to amplify
the inflammatory response. Interestingly, serum C3
consumption is also a marker of adverse outcome in
AAV. [26]
Clinical manifestations
AAVs are systemic diseases. However, ‘limited’ forms may
occur when they are confined to single organs. Table 3 re-
ports the main demographic and clinical characteristics of
two recently published series of paediatric AAV, one com-
ing from North America [3] and one from France [13].
These series were selected because they represent different
continents, were comprised of both GPA and MPA pa-
tients, provided detailed clinical phenotyping of the cases
and their size was quite large. In the same table we also re-
port the preliminary, unpublished results of a multicentre
study conducted in Italy also including GPA and MPA pa-
tients. This study is still underway. Finally, the table reports
the results of a retrospective literature review on paediatric
EGPA [15].
Common clinical presentation of paediatric AAV in-
cludes constitutional symptoms in more than 50% of pa-
tients. Fever, fatigue, anorexia and weight loss may
precede the systemic organ manifestations and, as they
are mostly non-specific findings, the diagnosis of AAV
may be delayed. A delay in diagnosis is particularly
found in patients with mild renal or otolaryngological
manifestations [27].
Table 3 Main demographic and clinical characteristics of childhood-onset GPA, MPA and EGPA in two large published series (Cabral
et al. and Sacri et al.), our unpublished Italian cohort and a literature review (Zwerina et al.)
GPA MPA EGPA
Cabral et al.
[3]
Sacri et al.
[13]
Italian cohort
(unpublished)
Cabral et al.
[3]
Sacri et al.
[13]
Italian cohort
(unpublished)
Zwerina et al.
[15]
Total no. of patients 183 38 31 48 28 21 33
Female, no. (%) 113 (62) 21 (75) 22 (71) 35 (73) 34 (89) 11(52) 19 (58)
Caucasian, no. (%) 107 (59) 21 (75) 31 (100) 20 (42) 26 (68) 21 (100) 24 (73)
Median age (range) at diagnosis-
years
14 (2–18) 12.8 (10.1-
14.6)
14 (6–18) 12 (1–18) 11.2 (8.9-
12.3)
11 (6–17) 13 (2–18)
Median time (range) to
diagnosis- months
2.1 (0–73) 1.8 (0.8-5) 5 (0–60) 1.6 (0–39) 1.0 (0.6-
8.1)
2.5 (1–24) NA
Constitutional symptoms, no. (%) 160 (88) 23 (82) 21 (68) 41 (85) 29(78) 14 (67) NA
Fever 97 (53) 19 (68) 16 (52) 25 (52) 18 (50) 11 (52) NA
Fatigue 160 (88) 23 (82) 21 (68) 37 (77) 29 (78) 14 (67) NA
Renal involvement, no. (%) 151 (83) 22 (78) 20 (65) 36 (75) 36 (95) 20 (95) 5/32 (16)
Pulmonary involvement, no. (%) 136 (74) 19 (68) 16 (52) 21 (44) 11 (29) 8 (38) 29 (88)
ENT, no. (%) 128 (70) 21 (75) 24 (78) 0 (0) 0 (0) 0 (0) 20 (77)
Eye involvement, no. (%) 78 (43) 6 (21) 14 (45) 15 (31) 3 (8) 0 (0) NA
Cutaneous involvement, no. (%) 86 (47) 15 (54) 8 (26) 25 (52) 13 (34) 7 (33) 21 (66)
Gastrointestinal involvement, no.
(%)
66 (36) 5 (18) 2 (6) 28 (58) 4 (11) 4 (19) 12 (40)
Musculoskeletal involvement, no.
(%)
24 (14) 1 (4) 14 (45) 9 (19) 1 (3) 6 (29) 7 (22)
CNS involvement, no. (%) 36 (20) 1 (4) 2 (6) 10 (21) 2(5) 6 (29) NA
Cardiovascular involvement, no.
(%)
10 (5) NA 2 (6) 3 (6) NA 1 (5) 17 (55)
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In MPA, renal disease is the most frequent manifest-
ation on presentation, followed by systemic features,
musculoskeletal, cutaneous, lower respiratory tract and
gastrointestinal involvement in the absence of granu-
lomatous lesions [28]. As in adults, renal involvement in
MPA is usually under the form of rapidly progressive
glomerulonephritis. Lung involvement is less frequent
but can be life-threatening in some cases, especially
when alveolar haemorrhage occurs [29].
GPA is generally characterised by ear-nose-throat
(ENT) involvement followed by constitutional symp-
toms, renal, lower respiratory tract, musculoskeletal and
cutaneous involvement [28]. Frequent clinical features
are: rhinitis, sinusitis, nasal crusts, epistaxis, otitis media,
sensorineural or conductive hearing loss. In some cases,
necrotising and granulomatous lesions cause destruction
of the turbinates and nasal septum perforation. The
most frequent lung lesions are nodules tending to exca-
vation, single or multiple, sometimes confluent. In GPA,
the frequency of renal disease ranges from 50 to 100% of
children (in adults it is slightly less frequent) and the
clinical pictures range from isolated urinary abnormal-
ities (proteinuria, microscopic haematuria and/or blood
red casts) to rapidly progressive glomerulonephritis, with
consequent acute kidney injury.
In both GPA and MPA skin lesions can be present,
such as palpable purpura, livedo reticularis, nodules, and
non-specific rash. Up to one third of patients present
with nonspecific musculoskeletal symptoms such as
arthralgia, myalgia and sometimes arthritis. Neurological
involvement is uncommon (seizures being the most fre-
quent manifestation), with central nervous system in-
volvement apparently being more frequent than
peripheral neuropathy [3, 13].
These clinical features are usually shared by adult-
onset and paediatric AAV and, as reported in Table 3,
their frequency is quite homogeneous across the differ-
ent cohorts. Thus, apparently, the clinical phenotypes of
adult and paediatric forms are similar. There are, how-
ever, some differences: one of the most significant clin-
ical discrepancies appears to be the frequency of
subglottic stenosis. In childhood-onset AAV, the risk of
subglottic stenosis is 5-fold higher than in adult patients;
likewise, the risk of saddle nose deformity is also higher
in children. Why this occurs is still unclear [30]. It is
also interesting to note that peripheral neuropathy,
which occurs in approximately one third of adult MPA
or GPA patients [31], is extremely rare in paediatric
AAV (2% in our Italian cohort), although it must be ac-
knowledged that this clinical feature is not well de-
scribed in other childhood AAV series. Also, the
incidence of cardiovascular manifestations appears to be
lower in paediatric AAV; it can be hypothesized that car-
diovascular manifestations in AAV are the results of
vasculitis but also of underlying atherosclerosis, which is
obviously prevalent in the adult age.
Studies on the clinical phenotype of EGPA are, as
already stated above, limited to few case reports or small
case series and literature reviews. As in adult-onset
EGPA, the paediatric form usually presents with asthma,
eosinophilia, sinusitis, nasal polyps, and lung infiltrates.
As compared with adult-onset EGPA, paediatric EGPA
more frequently shows cardiomyopathy, which can ac-
count for the higher mortality rates described in paediat-
ric cases. Importantly, publication bias of the reports
(reviewed by Zwerina et al.) might have led to the inclu-
sion of more aggressive cases. Other clinical features are
skin lesions (usually purpura or urticarial skin rashes),
which are found in up to two thirds of the cases, and
gastrointestinal involvement. Interestingly, as in MPA
and GPA, also in EGPA the frequency of neuropathy
seems to be lower in paediatric than in adult-onset AAV.
[15] (Table 3)
Laboratory findings
ANCA positivity is common but not universal in
childhood-onset AAV, as is in adult patients. In the lar-
gest cohort published to date, Cabral et al. [3] reported
that PR3-ANCA and/or C-ANCA are positive in 67% of
GPA and in 17% of MPA patients, whereas MPO-ANCA
and/or P-ANCA are found in 55% of children with MPA
and in 26% of those with GPA. ANCAs are more fre-
quently negative in patients with limited disease forms
(especially the ones confined to the upper airway tract).
True dual ANCA-positivity is rare and raises suspicion
of drug-induced vasculitis. As in adults, paediatric pa-
tients with EGPA are often ANCA negative; ANCA
positivity, in fact, is found in 25% of paediatric EGPA (vs
35-40% of adults), usually with P-ANCA pattern or
MPO-specificity [15].
Non-specific laboratory findings in childhood AAV in-
clude high acute-phase reactant levels (erythrocyte sedi-
mentation rate and C-reactive protein); haematologic
abnormalities, particularly anaemia, are also common.
Histopathology: focus on renal lesions
The key histological feature of AAV is necrotising vascu-
litis, with few or no immune deposits, predominantly af-
fecting small vessels. This can be associated with
granulomatous lesions in GPA and eosinophil-rich (and
often granulomatous) inflammation in EGPA. Tissue bi-
opsies are crucial to make the diagnosis of AAV; based
on the evidence of histologically compatible lesions, one
can apply the classification criteria to define the different
vasculitic syndromes. Notwithstanding, not all patients
with AAV have diagnostic biopsies; this usually happens
because some affected sites (e.g. upper airway tract)
often yield non-diagnostic specimens, or because
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surrogate markers of vasculitis (e.g. subglottic stenosis,
cavitated lung nodules) together with a clinically com-
patible phenotype and ANCA-positivity can lead to the
diagnosis of AAV even in the absence of a biopsy [11].
However, when renal involvement is present in pa-
tients with suspected or confirmed AAV, renal biopsy
still remains the gold standard for the diagnosis and is
an important predictor of renal outcome. ANCA-
associated glomerulonephritis is characterised by pauci-
immune immunofluorescence, necrotising and cres-
centic lesions in the affected glomeruli at light micros-
copy and subendothelial oedema, microthrombosis and
degranulation of neutrophils at electron microscopy. Al-
though ANCA-associated glomerulonephritis is com-
monly described as a pauci-immune disease, some cases
display focal deposition of immunoglobulins and com-
plement fractions, especially C3 [26]; these patients have
a poorer prognosis [32]. Glomerulonephritis in MPA dif-
fers from GPA-associated forms for the lack of granu-
lomatous lesions and the more frequent occurrence of
chronic lesions (e.g. glomerulosclerosis, fibrous cres-
cents, interstitial fibrosis). From a clinical standpoint,
MPA patients also tend to have more frequent and more
severe renal involvement than those with GPA. In
addition to glomerular involvement, renal disease in
AAV also shows tubulointerstitial nephritis; tubular le-
sions are important predictors of outcome, especially in
patients treated with B-cell depleting therapy [33].
In 2010, an international working group of renal pa-
thologists proposed a histopathologic classification of
ANCA-associated glomerulonephritis, predictive of
long-term renal outcome in the adult population. The
renal pathological features were divided into four dis-
tinct categories: focal, crescentic, sclerotic and mixed
(Table 4). These categories predicted renal outcome in
the short and long-term: patients with focal lesions had
an excellent renal outcome, whereas renal survival was
poor in the sclerotic class [34]. This classification system
was confirmed not only in other adult cohorts [35], but
also in paediatric studies. In 2014, Noone et al. used this
histopathologic classification system in a retrospective
study including 40 children with biopsy-proven ANCA-
associated glomerulonephritis (MPA and GPA) followed
for a median follow-up of 2.4 years. As in adults, the
histopathological classification provided important prog-
nostic information, with rapid progression to end-stage
renal disease of patients in the sclerotic class, mild dis-
ease in the focal, and slow decline over 2 years in mixed
and crescentic classes. Interestingly, in patients with
renal relapse or progressive renal impairment, 80% of
those with a crescentic pattern progressed to a sclerotic
class on a second biopsy. These data suggest, for chil-
dren with extensive sclerotic features, that aggressive im-
munosuppression is unlikely to result in renal function
recovery, and that probably this should be avoided to
limit short- and long-term adverse events. Conversely,
patients with more florid lesions may require intensive
treatment [36]. However, future prospective studies are
needed for better optimisation of treatment based on
pathologic features.
Disease activity scoring
The Birmingham Vasculits Activity Score (BVAS) is a
comprehensive multisystem tool for standard assessment
of systemic vasculitis, used in adult clinical trials [37].
The latest version of this score is the BVAS V3 [38]. The
original BVAS was subsequently modified and is recom-
mended for use in AAV clinical trials as part of the Out-
come Measures in Rheumatology (OMERACT) core set
of outcome measures. In adults, the Vasculitis Damage
Index (VDI) is also used for the standardised clinical as-
sessment of damage in systemic vasculitides [39]. A
paediatric tool based on modifications to the BVASv3,
the Paediatric Vasculitis Activity Score (PVAS), was de-
veloped in the 2012 by Dolazalova et al., but needs fur-
ther validation in independent data set. The score ranges
from 0 to 63 with higher scores indicating higher disease
activity [40, 41]. The Paediatric Vasculitis Damage Index
(PVDI) is based on a modified version of the adult VDI
tool; the score ranges from 0 to 73, with higher scores
indicating increased organ damage. Despite the fact that
the paediatric version is not yet formally validated, it
was used in a retrospective experience on childhood-
onset EGPA in the UK [42].
Treatment and outcome
Advances in the treatment of systemic vasculitis have
significantly improved patient outcomes in the last de-
cades. The introduction of glucocorticoids and cyclo-
phosphamide (CYC) dramatically improved the
prognosis of affected patients, with approximately 80%
surviving at 5 years compared with a 1-year mortality of
80% in untreated adult patients [43]. In the absence of
any controlled trials in paediatric AAV, treatment re-
mains based on adult data and is structured on a se-
quential approach comprising remission-induction and
remission-maintenance phases.
Table 4 Berden’s classification [34] of ANCA associated
glomerulonephritis
Class
Focal ≥50% normal glomeruli
Crescentic ≥50% glomeruli with cellular crescents
Mixed <50% normal, < 50% crescentic, < 50% globally sclerotic
glomeruli
Sclerotic ≥50% globally sclerotic glomeruli
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For remission-induction of organ- or life-threatening
AAV in adults, the EULAR-ERA EDTA recommenda-
tions indicate treatment with a combination of glucocor-
ticoids and either CYC or rituximab [44]. High-dose
glucocorticoids and CYC (either oral or intravenous) for
3–6 months are considered the gold standard of treat-
ment also in children. As an alternative to oral daily
CYC, the intermittent intravenous pulse regimen
(15 mg/kg/pulse, maximum 1.2 g, every 2–3 weeks for
3–6 months) reduces cumulative CYC exposure [45–47],
and is therefore routinely used in children. With regards
to rituximab, two randomised trials in adult patients
demonstrated its non-inferiority to CYC for remission
induction in AAV [48, 49]. The EULAR-ERA EDTA rec-
ommendations suggest RTX be considered for treatment
of children not responding to conventional treatments
and for patients with relapsing disease [50]. As opposed
to CYC, rituximab does not impair fertility and carries
an apparently lower malignancy risk. This is why, despite
the lack of solid data in children, its use in the paediatric
population has substantially increased; a recent study of
children hospitalised for AAV in the United States has
shown a shift from the use of CYC to the use of rituxi-
mab [51]. However, larger studies with long-term follow-
up are needed to establish the efficacy and safety of ri-
tuximab in children. Basu et al. showed the efficacy of a
sequential regimen of rituximab induction followed by
mycophenolate mofetil maintenance (2–3 years) in 11
children with MPA. After a median follow-up of
20.9 months, 73% of patients were off steroids (but still
on mycophenolate) and 82% never relapsed. Mycophe-
nolate mofetil has been tested also as induction therapy
for AAV in the MYCYC trial (clinicaltrials.gov
NCT00414128), a recently completed study whose re-
sults are awaited soon; MYCYC also included paediatric
patients. Other small, non-randomised studies used my-
cophenolate for induction in adults, with generally posi-
tive results [52]. In AAV patients with limited forms or
non-organ threatening manifestations, remission can be
obtained with methotrexate, which proved of equal effi-
cacy to CYC in adult patients with this disease subset
enrolled in the NORAM trial [53]. On the other hand,
very severe cases, presenting with rapidly progressive
renal failure or alveolar haemorrhage, may benefit from
the addition of plasma exchange to standard CYC-based
therapies [54]. In the largest published cohort of paediat-
ric MPA and GPA, Cabral et al. report the use of plasma
exchange in 21% of the cases [3].
Once remission has been induced, maintenance with
drugs other than CYC is recommended. Azathioprine
(AZA) is the mainstay of remission maintenance since
the publication of the CYCAZAREM trial, which showed
that its ability to prevent relapses was similar to that of
CYC [55]. Other options are available such as
methotrexate [56]. Mycophenolate mofetil proved infer-
ior to AZA in a randomised trial, therefore it is not rec-
ommended as first-line maintenance therapy [57].
Finally, a recent trial compared low-dose rituximab to
azathioprine for remission maintenance: rituximab-
treated patients had significantly fewer relapses than the
AZA-treated ones [58]. Remission maintenance should
be continued for at least 18–24 months.
AAVs are usually considered chronic-relapsing disor-
ders; at least in adults, the frequency of relapses is sig-
nificantly higher in GPA or PR3-ANCA positive patients
than in those with MPA or with MPO-ANCA. As long-
term follow-up studies of large cohorts are lacking, the
precise frequency of relapse in paediatric AAV is still un-
clear. In a retrospective French study of 35 AAV patients
followed for a median of 8 years, relapse rates ranged
from 33% in MPA to 50% in EGPA and 83% in GPA
[59]. This underlines the importance of a careful follow-
up and a prolonged remission maintenance therapy.
AAV patients accumulate damage over time, as a
result of both the disease itself and treatment-related
toxicity [60]. The risk of infection and infertility is
significant; moreover, particularly in children exposed
to high cumulative CYC doses, surveillance for neo-
plasms is mandatory. Common sequelae of AAV in-
clude saddle nose deformity and subglottic stenosis
(in GPA), asthma and chronic sinusitis (particularly
in EGPA), peripheral neuropathy with sensori-motor
deficits, and particularly chronic renal failure. Renal
disease is an important determinant of long-term
prognosis and morbidity in paediatric AAV; it is
more frequent and severe in MPA than in GPA,
whereas it is usually mild and tends not to progress
to end-stage renal disease in EGPA. In a study
reviewing seven reports of GPA and MPA in chil-
dren, the rate of end-stage renal disease ranged be-
tween 29% and 40% in MPA, whereas it was around
10% in GPA [60]. In a single-centre, cohort study of
40 well-characterised patients with ANCA-associated
glomerulonephritis, after a median follow-up of
2.4 years, 33.3% progressed to end-stage renal dis-
ease whereas 42.4% developed chronic kidney disease
not necessitating renal replacement therapy [36]. As
reported above, most of the studies that considered
renal histology at diagnosis showed that the histo-
logical category predicted renal survival, with the
sclerotic category portending a poorer outcome as
compared to the other classes. In patients who de-
velop end-stage renal disease, renal transplantation is
a feasible treatment option, although data on chil-
dren are still limited.
Fortunately, mortality rates are low in paediatric AAV
and usually do not exceed 5-10% [36, 59]. Childhood-
onset EGPA patients only seem to have a poorer survival
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(mortality rates of 15-18%), which is probably due to the
relatively high frequency of cardiac involvement [17, 42];
these data, however, must be taken with caution as they
are based on case reports or small case series.
Conclusions
AAVs are rare diseases in childhood, they may be severe
and organ- or life-threatening. Their clinical presenta-
tion is often similar to that of adult patients, although
some differences exist. Renal involvement drives the
prognosis of paediatric AAV, with end-stage renal dis-
ease requiring dialysis or transplantation being one of
the most severe long-term complications. The treatment
of paediatric AAV still relies on the studies performed in
adults; induction with CYC has been the mainstay of ini-
tial therapy, although the efficacy of RTX demonstrated
in adults has made this treatment an attractive option in
children as well. Although the long-term outcome of
paediatric AAV seems more favourable than that ob-
served in adults, larger multicentre studies are needed to
better define the prognosis of these patients.
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